August 15, 2017
Former CEO of Sanofi Pasteur to advise Boston-based company on the development of next generation vaccines on the MIMIX sustained-release microneedle platform
BOSTON, Massachusetts—August 14th, 2017—Vaxess Technologies, Inc., an innovative life sciences company developing novel vaccine stabilization and delivery technologies, announced today that Wayne Pisano has joined the company’s Board of Advisors. Mr. Pisano brings over 20 years of vaccine development leadership experience, including as President and CEO of Sanofi Pasteur, the world’s largest vaccine company. Mr. Pisano’s expertise will contribute to Vaxess’s advancement of the MIMIX microneedle platform for controlled intradermal vaccine delivery. The MIMIX platform combines improved efficacy through “infection mimicry” with simplified administration and delivery.
During Mr. Pisano’s tenure as President and CEO, Sanofi Pasteur distributed more than one billion doses of vaccines protecting against 20 infectious diseases to 500 million people worldwide every year, accounting for 25% of the global vaccine market. The company also became the world’s leading manufacturer of influenza vaccines with approximately 50% of global sales. Mr. Pisano also served on the supervisory board of Sanofi Pasteur MSD, a joint venture with Merck & Co. for the marketing of vaccines in Europe. More recently, Mr. Pisano was President and CEO of VaxInnate, a biotechnology company that worked on developing novel vaccines for infectious diseases such as influenza. Mr. Pisano serves on the Board of Directors for AERAS, the TB vaccine R&D Foundation, Immunovaccine Inc., a clinical stage immune-oncology and vaccine company and is the Chairman of Oncolytics Inc., a clinical stage immune-oncology company.
“Vaccines have played a major role in reducing the burden of disease over the last several decades, but there still remains a great need for more effective next-generation products, particularly in fields like influenza,” said Mr. Pisano. “The MIMIX microneedle patch has the potential to be a unique step in this direction as it combines shelf-stability and simplified administration with improved efficacy. I’m excited to work with the Vaxess team to move this product forward.”
“Wayne’s career is highlighted by the successful launch of products that combine commercial success with tremendous positive impacts on global health,” said Vaxess CEO Michael Schrader. “We’re excited to work with him to accelerate the launch of similarly impactful products on the MIMIX platform.”
About Vaxess Technologies
Vaxess Technologies is a pre-clinical stage company developing vaccines and immunotherapies on its novel technology platforms, including the MIMIX microneedle patch for sustained intradermal delivery. In addition to developing products in-house, Vaxess works with strategic partners to develop prophylactic and therapeutic products that are both more effective and more stable to enable truly global access to life-saving healthcare. For more information please visit the company website at www.vaxess.com or send additional inquiries to firstname.lastname@example.org.